Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway

---
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Vote:
0 0
Previous Visa and Global Fashion Agenda Back Emerging Designers with Circular Fashion Programme
Next O'S BUBBLE & PINK ROCKET: WHEN SWEET MEETS SPICY, 'SWICY' A NEW CATEGORY IS BORN

Related News

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease

Skyhawk Therapeutics Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial

Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test

menu
menu